Aquinox Pharmaceuticals Announces First Quarter 2018 Financial Results

- May 8th, 2018

Aquinox Pharmaceuticals (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the first quarter ending March 31, 2018. As quoted in the press release: “The first quarter was important as we surpassed recruitment targets and completed …

Aquinox Pharmaceuticals (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers, today provided a corporate update and reported financial results for the first quarter ending March 31, 2018.

As quoted in the press release:

“The first quarter was important as we surpassed recruitment targets and completed enrollment of the LEADERSHIP 301 Phase 3 clinical trial in subjects with interstitial cystitis/bladder pain syndrome (IC/BPS),” said David Main, President & CEO of Aquinox. “IC/BPS remains an area of high unmet medical need with few effective treatments available. We remain on track for sharing the topline results of this trial in Q3.”

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Leave a Reply